Nordic Life Science
The latest business news
TFS International has announced an agreement with the Pharma Intelligence division of Informa for their global research and development (R&D) platform – Citeline. “At TFS we are already proud of
The company provides an update on its clinical development programme, including updated guidance on expected milestones for the pivotal PARADIGME trial, and its financial outlook. A re-assessment of expected recruitment
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
AstraZeneca announces results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial. The results demonstrates a risk reduction of 19% in MACE (the composite of CV death, myocardial
The company has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on
Bavarian Nordic announces positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study achieved both of its primary endpoints, demonstrating IMVAMUNE’s efficacy in
The company has completed the safety lead-in cohort and preliminary immune activation data in the phase I/II trial of ONCOS-102 in mesothelioma in combination with standard of care chemotherapy has been announced. The trial is a randomized phase
The results from the SUSTAIN 7 trial, investigating the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide,
AstraZeneca announces results from their Phase III KRONOS trial showing PT010 demonstrated a statistically significant improvement in eight out of nine lung function primary endpoints based on forced expiratory volume
Swedish Orphan Biovitrum announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate
The US Food and Drug Administration has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who
The company has received authorization to conduct a phase I/II clinical study on the quadrivalent influenza vaccine candidate Immunose FLU, a novel nose drop formulation based on the company´s technology
The latest research findings from the Nordic region
The University of Helsinki has recruited Professor Mark Daly of the Broad Institute of MIT and Harvard and Massachusetts General Hospital to lead the Institute for Molecular Medicine Finland (FIMM).
Two of the Research Council of Norway’s three Awards for Young Outstanding Researchers have been awarded this year to cancer researcher Kyrre Eeg Emblem and nanotechnologist Øivind Wilhelmsen. The winners
A study made by scientists from the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark, published by PNAS, suggests that cells can be engineered to overcome
The Nordic Investment Bank (NIB) and the special-purpose vehicle SKR Spallation AB have signed a 23-year loan agreement of EUR 30 million for the construction of offices and laboratories at the site
Researchers from Uppsala University and Karolinska Institutet in Sweden present in the journal Nature a detailed molecular atlas of the cells that form the brain’s blood vessels and the life-essential blood-brain barrier.
Cholesterol metabolites cause specific immune cells in the large intestine to move, which lies behind the formation of the immune system’s important lymphoid tissue in the intestine, reports researchers at